Diana Cristina Henao-Carrillo

Diana Cristina Henao-Carrillo

Auto-generated profile, based on publicly available information

Diana Cristina Henao-Carrillo

Pontificia Universidad Javeriana, Bogotá, Colombia; Hospital Universitario San Ignacio, Endocrinology Unit, Bogotá, Colombia

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2021 in Diabetes & Metabolic Syndrome: Clinical Research & Reviews
Verified
Journal Article
Closed access
AGAna M. Gómez
Ana M. Gómez
DHDiana Henao
Diana Henao
DPDarío Parra
Darío Parra
AKAlfonso Kerguelen
Alfonso Kerguelen
MPMarisol Vergara Pinilla
Marisol Vergara Pinilla
MRMARTIN RONDON
MARTIN RONDON

1 March 2021 in Diabetes & Metabolic Syndrome: Clinical Research & Reviews
Verified
Journal Article
Closed access
AGAna María Gómez
Ana María Gómez
DHDiana Cristina Henao
Diana Cristina Henao
OMOscar Mauricio Muñoz
Oscar Mauricio Muñoz
PAPablo Aschner
Pablo Aschner
CYCarlos Augusto Yepes
Carlos Augusto Yepes
GUGuillermo E. Umpierrez
Guillermo E. Umpierrez

1 February 2017 in Diabetes Technology & Therapeutics
Verified
Journal Article
Closed access
AGAna María Gómez
Ana María Gómez
LCLisseth Fernanda Marín Carrillo
Lisseth Fernanda Marín Carrillo
OVOscar Mauricio Muñoz Velandia
Oscar Mauricio Muñoz Velandia
MSMartín Alonso Rondón Sepúlveda
Martín Alonso Rondón Sepúlveda
CCCarol M. Arévalo Correa
Carol M. Arévalo Correa
DCDiana Cristina Henao Carrillo
Diana Cristina Henao Carrillo
Background: Literature supports short-term efficacy and safety of Sensor Augmented Insulin Pump (SAP) therapy in patients with type 1 diabetes (T1D). However, no data are available showing long-term outcomes. Our study describes the long-term outcomes of SAP therapy with low-glucose suspend feature (SAP+LGS) in hypoglycemia in a Colombian population with T1D and hypoglycemia. Methods: A cohort study was conducted with T1D patients receiving SAP+LGS therapy who initiated this therapy because of hypoglycemia at San Ignacio University Hospital diabetes center in Bogotá, Colombia. Glycated hemoglobin (A1c) was assessed at least every 6 months, severe hypoglycemia (SH) and hypoglycemia unawareness (HU) incidence yearly. Adherence to therapy was also evaluated. Results: One hundred eleven patients were included in the analysis. Total daily insulin dose was reduced during follow-up (mean difference −0.22 U/kg; 95% confidence interval [CI] −0.18 to −0.26; P < 0.001). A1c levels were reduced from a baseline value of 8.8% ± 1.9% to 7.5% ± 1.0% at 5 months (mean difference −1.3%; 95% CI −1.09 to −1.50; P < 0.001) and 7.1% ± 0.8% (mean difference −1.7%; 95% CI −1.59 to −1.90; P < 0.001) at the end of follow-up (47 months on average). The incidence of SH and HU episodes decreased significantly since the first year, and this effect was maintained over time ( P < 0.001). Conclusions: SAP+LGS therapy in T1D patients with hypoglycemia led to a significant and sustained decrease in A1c during long periods of follow-up, as well as a significant reduction in SH and HU. Future randomized clinical trials are desired.

1 September 2017 in Medical Devices: Evidence and Research
Verified
Journal Article
Open access
PDF file
AGAna Maria Gomez
Ana Maria Gomez
DCDiana Cristina Henao Carrillo
Diana Cristina Henao Carrillo
OMOscar Munoz
Oscar Munoz
Continuous glucose monitoring (CGM) is a tool that allows constant evaluation of glycemic control, providing data such as the trend and fluctuation of interstitial glucose levels over time. In clinical practice, there are two modalities: the professional or retrospective and the personal or real-time CGM (RT-CGM). The latest-generation sensors are more accurate and sensitive for hypoglycemia, improving adherence to self-monitoring, which has allowed optimizing glycemic control. The development of algorithms that allow the suspension of the infusion of insulin during hypoglycemia gave rise to the integrated therapy or sensor-augmented insulin pump therapy with low glucose suspend, which has proven to be an effective and safe alternative in the treatment of diabetic patients with high risk of hypoglycemia. The objective of this review is to present the evidence of the advantages of RT-CGM, the clinical impact of integrated therapy, and cost-effectiveness of its implementation in the treatment of patients with diabetes mellitus.

1 July 2017 in Diabetes Technology & Therapeutics
Verified
Journal Article
Closed access
AGAna María Gómez
Ana María Gómez
LCLisseth Fernanda Marín Carrillo
Lisseth Fernanda Marín Carrillo
CCCarol M. Arévalo Correa
Carol M. Arévalo Correa
OVOscar Mauricio Muñoz Velandia
Oscar Mauricio Muñoz Velandia
MSMartín Alonso Rondón Sepúlveda
Martín Alonso Rondón Sepúlveda
DCDiana Cristina Henao Carrillo
Diana Cristina Henao Carrillo
Background: Pregnancy in women with type 1 diabetes (T1D) is associated with increased risk of maternal complications and neonatal morbidity and mortality. Optimizing glycemic control improves these outcomes. Objective: To describe the experience of using sensor-augmented insulin pump therapy (SAPT) and SAPT + low-glucose suspension (LGS) on pregnant women with T1D, including neonatal and maternal outcomes. Methods: A prospective observational study was conducted in women with T1D who started SAPT and SAPT + LGS before or during pregnancy at the San Ignacio University Hospital Diabetes Center in Bogotá, Colombia. The main indication was severe hypoglycemia (SH) and poor glycemic control. Glycated hemoglobin (A1c), hypoglycemia, and maternal and fetal outcomes were assessed. Results: Thirty-four pregnant women with T1D on SAPT and SAPT + LGS were included. Sixteen patients started therapy during pregnancy at a mean gestational age of 17.6 ± 8.3 weeks. Mean preconceptional A1c was 8.24% ± 2.02%. Absolute reduction of A1c level from prepregnancy to third trimester was −1.63% (P < 0.0001), with a significant clinical and statistical reduction in both groups, women who initiated SAPT before or during pregnancy. 52.9% of patients in second trimester and 66.6% in third trimester achieved A1c <6.5%, respectively. 91.1% underwent cesarean section. The main reasons were iterative cesarean (30%), fetal distress (20%), and preeclampsia (16%). The median gestational age at delivery was 37 weeks and 15 pregnancies resulted in preterm delivery. There was neither maternal–fetal mortality nor severe hypoglycemic episodes. Two patients had diabetic ketoacidosis. Conclusions: In pregnant patients with T1D and high risk of hypoglycemia, SAPT and SAPT + LGS should be considered as a therapeutic alternative for A1c reduction with a low risk of SH. However, additional studies are required to evaluate the efficacy and safety of this therapy during pregnancy.

1 June 2018 in Journal of Clinical & Translational Endocrinology
Verified
Journal Article
Open access
DHDiana Cristina Henao-Carrillo
Diana Cristina Henao-Carrillo
OMOscar M. Muñoz
Oscar M. Muñoz
AGAna M. Gómez
Ana M. Gómez
MRMARTIN RONDON
MARTIN RONDON
CCChristian Colón
Christian Colón
APAna María Perea
Ana María Perea
Degludec (IDeg) is an ultralong-acting insulin, with stable pharmacodynamic profile which leads to lower fluctuations in glucose levels. The effect of IDeg has not been specifically assessed in patients with unstable diabetes, defined as increased glycemic variability (GV). A prospective before-after pilot study was conducted, including patients managed at Hospital Universitario San Ignacio in Bogotá, Colombia. The impact of the switch from a Glargine or Detemir insulin to a basal insulin regimen with IDeg for 12 weeks on GV measured by continuous glucose monitoring, on A1c levels, and on the incidence of episodes of global and nocturnal hypoglycemia was assessed in a group of patients with (coefficient of variation >34%) or without increased basal GV using a Generalised Estimating Equation (GEE) analysis. 60 patients with basal bolus therapy and history of hypoglycemia were included. 18 patients had High GV (HGV). In this group a significant reduction of 11.1% of CV (95% CI: 6.3, 15.9, p = 0.01) was found. GEE analysis confirmed a higher impact over time on patients with HGV (p < 0.001). The percentage of patients with at least 1 episode of hypoglycemia decreased from 66.6% to 22.2% (p = 0.02) and from 37.14% to 5.71% (p < 0.01) for global and nocturnal hypoglycemia, respectively. Changes were not significant in patients with low GV. A reduction of A1c was observed in both groups (p < 0.001). The results suggest that treatment with IDeg reduces GV, A1c levels and the incidence of global and nocturnal hypoglycemia events in patients with HGV, but not in patients with low GV.